TP53 and atherosclerosis: Notably, in addition to identifying a different mechanism through which CHIP mutations contribute to atherogenesis, this study also offered a link between cytotoxic chemotherapy, which often results in mutations in DNA damage response genes (such as TP53), and subsequent risk of ASCVD.